V-Co Investors 3 LLC, which holds a ten percent ownership stake in Vivos Therapeutics, Inc. (NASDAQ: VVOS), reported a share purchase late in March that materially increased its common stock holdings.
According to a Form 4 filing with the Securities and Exchange Commission, the entity purchased 1,353,625 shares of Vivos common stock on March 31, 2026, at a per-share price of $1.34. The aggregate value of that transaction was $1,813,857. The filing additionally shows that V-Co Investors 3 LLC obtained 429,957 Pre-Funded Warrants, 1,783,582 Series A Common Stock Warrants, and 1,783,582 Series B Common Stock Warrants in the same reporting period.
The Form 4 names Michael C. Skaff as Managing Director of SP Manager LLC, which serves as manager of V-Co Investors 3 LLC. The filing documents the ownership and the newly acquired instruments without further commentary on intent or future plans.
Vivos shares have displayed some recent volatility. The stock advanced 10.92% over the prior week to the purchase date, yet remained down 58.75% over the preceding six months. Separately, InvestingPro analysis cited in public reporting indicates the stock appears undervalued at current levels when compared with Fair Value estimates.
Beyond the insider purchase, Vivos Therapeutics disclosed two operational and financing developments. First, the company has secured in-network status with several commercial health insurance payers and with Medicare in Nevada. This development enables insurance coverage for Vivos appliances and treatments in the Las Vegas metropolitan area, broadening access for patients who previously lacked in-network options.
Second, Vivos entered into a definitive agreement for the immediate exercise of outstanding warrants. Under that arrangement, up to 1,982,356 shares may be purchased at a reduced exercise price of $2.34 per share, which is expected to produce approximately $4.64 million in gross proceeds for the company. The filing notes the original exercise prices on those warrants ranged from $3.83 to $5.05 per share. The projected proceeds are stated before deduction of placement agent fees and offering expenses.
These items - a concentrated insider acquisition, expanded insurance coverage in a defined geography, and an agreement to exercise warrants at a discounted price - represent a combination of capital markets activity and operational progress for Vivos. The Form 4 provides the regulatory record of the insider transaction; separate company disclosures describe the payer network development and the financing transaction expected to deliver near-term gross proceeds.
Investors and analysts seeking deeper company valuation and comparative analysis can access a Pro Research Report on VVOS that is part of InvestingPro's coverage of more than 1,400 U.S. equities.